Valuation: Absci Corporation

Market Cap 1.73B 1.51B 1.4B 1.29B 2.44B 166B 2.48B 16.7B 6.55B 81.51B 6.51B 6.37B 281B P/E 2026 *
-13x
P/E 2027 * -15.4x
Enterprise Value 1.6B 1.4B 1.29B 1.19B 2.25B 154B 2.29B 15.41B 6.04B 75.21B 6.01B 5.87B 259B EV / Sales 2026 *
282x
EV / Sales 2027 * 89.3x
Free-Float
87.96%
Yield 2026 *
-
Yield 2027 * -
1 day+0.20%
1 week-9.71%
Current month-11.73%
1 month+50.44%
3 months+224.76%
6 months+205.37%
Current year+193.12%
1 week 10.04
Extreme 10.04
12
1 month 6.83
Extreme 6.83
12.06
Current year 2.24
Extreme 2.24
12.06
1 year 2.24
Extreme 2.24
12.06
3 years 1.11
Extreme 1.1111
12.06
5 years 1.11
Extreme 1.1111
31.53
10 years 1.11
Extreme 1.1111
31.53
Manager TitleAgeSince
Chief Executive Officer 36 2011-07-31
Director of Finance/CFO 53 2023-08-30
Chief Tech/Sci/R&D Officer - 2025-07-31
Director TitleAgeSince
Director/Board Member 36 2010-12-31
Director/Board Member 59 2020-07-31
Director/Board Member 57 2022-01-06
Date Insider Type Main position Quantity % Market Cap.
06-29Buy

Director

12,900 0.0076%
06-23Tax

Founder

-59,896 0.0384%
06-03Free

Director

49,900 0.0320%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%-9.71%+284.59%+411.50% 1.73B
-0.45%+1.50%+3.19%+7.46% 50.35B
+0.55%-2.88%+382.07%+593.81% 39.32B
+0.13%-0.19%+29.79%-6.00% 34.69B
+0.86%-0.78%+21.58%+56.15% 34.08B
-1.31%-3.03%+2.51%+25.24% 26.63B
+0.13%-0.52% - - 16.49B
+1.13%-1.85%+67.36%+120.46% 15.31B
-0.99%+2.00%+13.47%+16.45% 13.8B
+1.13%-0.44%+12.34%-31.79% 12.87B
Average +0.15%-1.71%+90.77%+132.59% 24.53B
Weighted average by Cap. +0.08%-0.79%+82.57%+124.49%

Financials

2026 *2027 *
Net sales 5.67M 4.96M 4.58M 4.23M 7.97M 545M 8.12M 54.63M 21.44M 267M 21.3M 20.83M 918M 17.68M 15.45M 14.28M 13.19M 24.84M 1.7B 25.29M 170M 66.81M 831M 66.39M 64.93M 2.86B
Net income -125M -109M -101M -93.31M -176M -12.01B -179M -1.2B -473M -5.88B -470M -459M -20.25B -121M -106M -97.85M -90.4M -170M -11.63B -173M -1.17B -458M -5.7B -455M -445M -19.62B
Net Debt -134M -117M -108M -99.95M -188M -12.86B -192M -1.29B -506M -6.3B -503M -492M -21.69B -154M -135M -124M -115M -216M -14.79B -220M -1.48B -582M -7.24B -578M -566M -24.94B
Logo Absci Corporation
Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Employees
140
Date Price Change Volume
26-07-14 US$10.23 +0.20% 3,287,544
26-07-13 US$10.21 -3.68% 2,925,498
26-07-10 US$10.60 -7.59% 4,696,717
26-07-09 US$11.47 +3.33% 4,970,931
26-07-08 US$11.10 -2.03% 6,599,911
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
10.23USD
Average target price
13.78USD
Spread / Average Target
+34.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABSI Stock